Previous Close | 2.1700 |
Open | 2.1500 |
Bid | 2.1300 x 800 |
Ask | 2.1400 x 1800 |
Day's Range | 2.1100 - 2.2150 |
52 Week Range | 2.0000 - 14.4200 |
Volume | |
Avg. Volume | 1,326,035 |
Market Cap | 144.134M |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0740 |
Earnings Date | Mar 11, 2022 - Mar 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.67 |
The big shareholder groups in Gritstone bio, Inc. ( NASDAQ:GRTS ) have power over the company. Generally speaking, as a...
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio